Asthma Therapeutics Market Report 2026

Asthma Therapeutics Market Overview

• Asthma Therapeutics market size has reached to $33.11 billion in 2025 • Expected to grow to $47.87 billion in 2030 at a compound annual growth rate (CAGR) of 7.6% • Growth Driver: Increasing Prevalence Of Asthma Fueling The Growth Of The Market Due To Rising Exposure To Air Pollution And Associated Health Risks • Market Trend: Advancements In Anti Inflammatory Rescue Inhalers Improve Symptom Relief And Airway Inflammation Management In Asthma • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Asthma Therapeutics Market?

Asthma therapeutics refers to the range of medications and treatments used to manage and relieve asthma symptoms, a chronic respiratory condition characterized by airway inflammation and constriction. These therapies include quick-relief medications for immediate symptom control and long-term control drugs that help reduce airway inflammation and prevent asthma attacks. The main types of drug classes included in asthma therapeutics are inhaled corticosteroids (ICS), long-acting beta agonists, leukotriene receptor antagonists, short-acting beta agonists, biologics, and combination inhalers. Inhaled corticosteroids are medicines breathed directly into the lungs to reduce inflammation and swelling in the airways, making it easier to breathe for people with asthma. They are used at different treatment stages, such as acute treatment, long-term control, preventive treatment, maintenance regimens, and rescue medications, by various routes of administration, including oral, inhaled, intravenous, and subcutaneous. They are different distribution channels, such as hospital pharmacies, retail pharmacies, and online pharmacies, and are used by several end-users, including hospitals, home care, and specialty clinics.

What Is The Asthma Therapeutics Market Growth Forecast?

The asthma therapeutics market size is expected to see strong growth in the next few years. It will grow to $47.87 billion in 2030 at a compound annual growth rate (CAGR) of 7.6%. The growth in the forecast period can be attributed to development of novel biologics and combination therapies, expansion of telemedicine and digital health monitoring, growing preventive treatment awareness, increasing healthcare access in emerging markets, rising investment in research and drug development. Major trends in the forecast period include rising adoption of personalized asthma therapies, increase in inhaler and biologic usage, expansion of homecare and remote monitoring solutions, growing preference for combination inhalers, enhanced focus on pediatric and geriatric asthma care.

Global Asthma Therapeutics Market Segmentation

1) By Drug Class: Inhaled Corticosteroids (ICS), Long-Acting Beta Agonists (LABA), Leukotriene Receptor Antagonists (LTRA), Short-Acting Beta Agonists (SABA), Biologics, Combination Inhalers (ICS + LABA) 2) By Treatment Stage: Acute Treatment, Long-Term Control, Preventive Treatment, Maintenance Regimens, Rescue Medications 3) By Route Of administration: Oral, Inhaled, Intravenous, Subcutaneous 4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies 5) By End-User: Hospitals, Homecare, Specialty Clinics Subsegments: 1) By Inhaled Corticosteroids (ICS): Fluticasone, Budesonide, Beclomethasone, Mometasone, Ciclesonide 2) By Long-Acting Beta Agonists (LABA): Salmeterol, Formoterol, Indacaterol, Olodaterol 3) By Leukotriene Receptor Antagonists (LTRA): Montelukast, Zafirlukast, Pranlukast 4) By Short-Acting Beta Agonists (SABA): Albuterol (Salbutamol), Levalbuterol, Terbutaline 5) By Biologics: Omalizumab, Mepolizumab, Benralizumab, Dupilumab, Reslizumab 6) By Combination Inhalers (ICS + LABA): Fluticasone + Salmeterol, Budesonide + Formoterol, Mometasone + Indacaterol, Beclomethasone + Formoterol

What Is The Driver Of The Asthma Therapeutics Market?

The increasing prevalence of asthma is expected to propel the growth of the asthma therapeutics market going forward. Asthma refers to a long-term disease that causes inflammation and swelling of the airways, resulting in the narrowing of the airways that carry air from the nose and mouth to the lungs. The increasing prevalence of asthma is due to increasing pollutants, which irritate the airways and raise the risk of developing the condition. Asthma therapeutics help manage asthma by controlling airway inflammation, relieving symptoms, and preventing asthma attacks. For instance, in May 2025, according to the UK Parliament, a UK-based government body, there were 3,886,879 people over the age of six diagnosed with asthma in 2023-24, accounting for 6.5% of England’s population. Therefore, the increasing prevalence of asthma is driving the growth of the asthma therapeutics industry.

Key Players In The Global Asthma Therapeutics Market

Major companies operating in the asthma therapeutics market are Roche Holding AG, Merck & Co Inc., Pfizer Inc., AstraZeneca plc, Sanofi S.A., Novartis AG, GlaxoSmithKline plc, Boehringer Ingelheim GmbH, Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Sun Pharmaceutical Industries Ltd., Chiesi Farmaceutici S.p.A., Cipla Limited, Mylan N.V.

Global Asthma Therapeutics Market Trends and Insights

Major companies operating in the asthma therapeutics market are focusing on developing innovative solutions such as anti-inflammatory rescue inhaler to enhance symptom relief, inflammation control, and overall disease management. Anti-inflammatory rescue inhaler is a dual-action therapeutic approach that combines a fast-acting bronchodilator with an inhaled corticosteroid in a single inhaler, enabling capabilities such as rapid bronchodilation, on-demand inflammation reduction, and prevention of severe asthma attacks. For instance, in January 2024, AstraZeneca plc, a UK-based biopharmaceutical company, launched AIRSUPRA, an FDA-approved anti-inflammatory rescue inhaler designed to deliver immediate symptom relief alongside fast anti-inflammatory action, featuring as-needed dual-mechanism dosing, real-time airway inflammation suppression, and support in preventing exacerbation-related lung-function decline. AIRSUPRA improves asthma control, reduces the risk of severe attacks, and strengthens overall rescue-therapy effectiveness.

What Are Latest Mergers And Acquisitions In The Asthma Therapeutics Market?

In January 2025, Phillips Medisize, a U.S.-based contract development and manufacturing organization (CDMO), acquired Vectura Group Ltd. for an undisclosed amount. With this acquisition, Phillips Medisize aims to enhance its inhalation drug-delivery capabilities by integrating Vectura’s deep formulation and device expertise across dry powder inhalers, nebulizers, metered-dose inhalers, and nasal systems. Vectura Group Ltd. is a U.K.–based company that specializes in inhalation formulation, device development, and regulatory-support services.

Regional Insights

North America was the largest region in the asthma therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Asthma Therapeutics Market?

The asthma therapeutics market consists of revenues earned by entities by providing services such as prescription management, inhaler technique training, nebulization therapy, and allergy testing and immunotherapy. The market value includes the value of related goods sold by the service provider or included within the service offering. The asthma therapeutics market consists of sales of methylxanthines, anticholinergics, systemic corticosteroids, mast cell stabilizers, immunotherapy products, and adjunctive therapies. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Asthma Therapeutics Market Report 2026?

The asthma therapeutics market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the asthma therapeutics industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.